Review of effects of anti-VEGF treatment on refractive error

• Published in: Eye and Brain Vol. 8; no. Issue 1; pp. 135 - 140
• Main Authors: Mintz-Hittner, Helen A, Geloneck, Megan M
• Format: Journal Article Book Review
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2016; Taylor & Francis Ltd; Dove Medical Press
• Subjects: aflibercept; Age; Analysis; bevacizumab; Birth weight; Care and treatment; Cryotherapy; Lasers; Macular degeneration; Monoclonal antibodies; myopia; ranibizumab; refraction; Refractive errors; Retina; retinopathy of prematurity; Review; ROP; Vascular endothelial growth factor; ROP; refraction; aflibercept; bevacizumab; myopia; ranibizumab; retinopathy of prematurity
• ISSN: 1179-2744; 1179-2744
• DOI: 10.2147/eb.s99306

To examine the effect of anti-vascular endothelial growth factor (anti-VEGF) agents on refractive error in the setting of retinopathy of prematurity (ROP) through a review of the literature, a PubMed search was performed of appropriate search terms, and the results of all relevant studies were extracted and compiled. Eleven relevant articles were identified in the literature, totaling 466 eyes, treated with varied anti-VEGF agents (bevacizumab, ranibizumab, and aflibercept) with mean spherical equivalent refractions ranging from +0.75 D to -3.57 D, with prevalence of high myopia ranging from 0 to 35%. Anti-VEGF monotherapy for ROP leads to low levels of myopia, and there may be a differential effect of specific anti-VEGF agents utilized on refractive outcomes.